---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-24-000029"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T13:39:00.276051+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neurogene Reports Positive Initial Safety Data from Phase 1/2 Gene Therapy Trial for Rett Syndrome

## Summary
- NGN-401 generally well-tolerated in three patients with multiple months of follow-up.
- No treatment-emergent or procedure-related serious adverse events or MeCP2 overexpression toxicity observed.
- Data presented at ASGCT Annual Meeting; includes one patient with mild variant predicted to retain residual MeCP2 function.
- Company expects interim efficacy readout in Q4 2024.

## SEC filing metadata
- accession: 0001404644-24-000029
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000029/0001404644-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464424000029/ngne-20240422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-24-000029
- JSON: https://secwatch.observer/filing/0001404644-24-000029.json
- Plain text: https://secwatch.observer/filing/0001404644-24-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.